CN Patent

CN114762682A — 一种普瑞巴林缓释片

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2022-07-19 · 4y expired

What this patent protects

本公开提供一种普瑞巴林缓释片，含有作为活性成分的普瑞巴林或其盐或水合物、凝胶骨架材料以及溶胀材料；其中凝胶骨架材料含有海藻酸盐和钙盐，溶胀材料含有聚氧乙烯N60K，通过改善制剂处方在溶出介质pH6.8磷酸盐溶液中的释放速度和释放度，减小与溶出介质0.06mol/L盐酸溶液中的差异，提高药物在餐后和空腹下的生物利用度。

USPTO Abstract

本公开提供一种普瑞巴林缓释片，含有作为活性成分的普瑞巴林或其盐或水合物、凝胶骨架材料以及溶胀材料；其中凝胶骨架材料含有海藻酸盐和钙盐，溶胀材料含有聚氧乙烯N60K，通过改善制剂处方在溶出介质pH6.8磷酸盐溶液中的释放速度和释放度，减小与溶出介质0.06mol/L盐酸溶液中的差异，提高药物在餐后和空腹下的生物利用度。

Drugs covered by this patent

Patent Metadata

Patent number
CN114762682A
Jurisdiction
CN
Classification
—
Expires
2022-07-19
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.